In an adult with tension‑type headache who has not achieved relief after an adequate trial of amitriptyline, what are the recommended next management steps?

Management of Tension-Type Headache Not Responding to Amitriptyline

If amitriptyline has failed to provide adequate relief for chronic tension-type headache, consider switching to mirtazapine or venlafaxine as second-line prophylactic agents, while ensuring the amitriptyline trial was adequate (50-100 mg daily for at least 8-12 weeks). 1

First: Verify Adequate Amitriptyline Trial

Before abandoning amitriptyline, confirm the following:

• Dosing was adequate: The 2024 VA/DoD guidelines recommend amitriptyline at 50-100 mg daily for chronic tension-type headache 1. Many patients are started on subtherapeutic doses (10-25 mg) 2. The FDA label indicates outpatients may require up to 150 mg daily 3.

• Duration was sufficient: Allow at least 8-12 weeks at therapeutic doses, as antidepressant effects may take up to 30 days to develop 3.

• Medication adherence: Verify the patient has been consistently taking the medication.

Second-Line Pharmacologic Options

Mirtazapine (Preferred Second-Line)

Mirtazapine is recommended as a second-choice drug for chronic tension-type headache prophylaxis 1. Evidence shows:

• Comparable efficacy to amitriptyline in reducing headache frequency 4
• Significantly fewer side effects than amitriptyline, particularly less anticholinergic burden (dry mouth, drowsiness) 4
• Acts selectively on noradrenalin and serotonin receptors 4
• Typical dose: 30 mg nightly

Venlafaxine (SNRI - Alternative Second-Line)

Venlafaxine is also listed as a second-choice prophylactic agent 1, though evidence is limited. One placebo-controlled trial showed no significant benefit over placebo for headache frequency 5.

What NOT to Do

Avoid switching to SSRIs (paroxetine, sertraline, fluoxetine, citalopram): High-quality evidence demonstrates SSRIs are not effective for tension-type headache prevention 5. Specifically:

• No reduction in headache frequency compared to placebo 5
• Less effective than amitriptyline for reducing analgesic medication use 5
• One study specifically showed paroxetine failed to improve chronic tension-type headache that had not responded to amitriptyline 6

Non-Pharmacologic Interventions to Add

The 2024 VA/DoD guidelines note that evidence for behavioral interventions is mixed or insufficient 1, but consider:

• EMG biofeedback: Has documented effect in tension-type headache 7
• Cognitive-behavioral therapy and relaxation training: Most likely effective 7
• Physical therapy or acupuncture: May be valuable options for frequent tension-type headache 7

Combining stress management therapy with pharmacologic treatment produces superior outcomes: 64% of patients achieved ≥50% reduction in headache index with combined therapy versus 38% with medication alone 8.

Common Pitfalls

1. Underdosing amitriptyline: Many clinicians use 10-25 mg doses 2, but evidence supports 50-100 mg daily 1, 9

2. Premature medication switching: Ensure adequate trial duration before declaring treatment failure

3. Trying SSRIs after amitriptyline failure: This approach lacks evidence and is likely futile 6, 5

4. Ignoring medication-overuse headache: Ensure patients are not overusing acute analgesics (>10-15 days/month), which can perpetuate chronic headache 7

5. Overlooking comorbid depression: Patients with chronic tension-type headache commonly have depression 10, which may require specific treatment

Practical Algorithm

1. Optimize amitriptyline to 50-100 mg daily if not already done
2. If inadequate response after 8-12 weeks → Switch to mirtazapine 30 mg nightly
3. Add behavioral therapy (stress management, biofeedback, or CBT) to pharmacotherapy
4. Monitor for 8-12 weeks on new regimen
5. If still inadequate → Consider venlafaxine or multidisciplinary headache clinic referral